logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Medications for Acute Bacterial Skin And Skin Structure Infection

    FiltersReset Filters
    6 results

    • dalvance

      (Dalbavancin)
      Allergan, Inc.
      Usage: DALVANCE® is indicated for treating acute bacterial skin and skin structure infections (ABSSSI) in adults and pediatrics caused by specific Gram-positive bacteria, including methicillin-susceptible and methicillin-resistant Staphylococcus aureus, and various Streptococcus and Enterococcus species. Usage should target infections caused by susceptible strains to minimize resistance.

    • kimyrsa

      (oritavancin diphosphate)
      Melinta Therapeutics, LLC
      Usage: KIMYRSA® is indicated for treating adult patients with acute bacterial skin and skin structure infections (ABSSSI) caused by specific Gram-positive bacteria, including methicillin-susceptible and resistant Staphylococcus aureus, various Streptococcus species, and vancomycin-susceptible Enterococcus faecalis. Use only for proven or suspected susceptible infections.

    • nuzyra

      (omadacycline)
      Paratek Pharmaceuticals, Inc.
      Usage: NUZYRA is indicated for the treatment of adult patients with community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI) caused by various susceptible microorganisms, including specific strains of bacteria like Streptococcus pneumoniae and Staphylococcus aureus.

    • orbactiv

      (oritavancin)
      Melinta Therapeutics, LLC
      Usage: ORBACTIV® (oritavancin) is indicated for treating adult patients with acute bacterial skin and skin structure infections caused by susceptible Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus and vancomycin-susceptible Enterococcus faecalis. It should be used to prevent drug-resistant bacteria and tailored based on culture results when available.

    • sivextro

      (tedizolid phosphate)
      Nabriva Therapeutics US, Inc.
      Usage: SIVEXTRO® is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in patients aged 12 and older, caused by susceptible Gram-positive bacteria, including MRSA. It should be used judiciously to prevent drug-resistant bacteria and guided by culture and susceptibility information.

    • zevtera

      (ceftobiprole medocaril sodium)
      La Jolla Pharmaceutical Company
      Usage: ZEVTERA is indicated for treating adult patients with Staphylococcus aureus bloodstream infections, acute bacterial skin and skin structure infections, and community-acquired bacterial pneumonia in pediatric patients (3 months to <18 years) caused by susceptible bacteria, including methicillin-resistant strains.